Authors
Latest:
Dr. Hensing Discusses Studies in Stage III NSCLCThomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non-small cell lung cancer (NSCLC).
Latest:
Dr. Hope on Challenges With 68Ga-PSMA-11 PET in Prostate CancerThomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.
Latest:
Thomas A. Neville, PhD, Discusses PSA Growth RateThomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.
Latest:
Dr. Butler on the Importance of Health Literacy InitiativesThomas Butler, MD, associate professor of interdisciplinary clinical oncology, Mitchell Cancer Center, discusses the importance of health literacy initiatives at the Association of Community Cancer Center (ACCC) National Oncology Conference.
Latest:
Future Directions in the Treatment of Recurrent or Metastatic Cervical CancerThe panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.
Latest:
An Individualized Approach to Treating Advanced RCCGrounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.
Latest:
Series Wrap-up: Novel Therapies for mRCCA panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
Latest:
Dr. Stinchcombe on the ALTA-1L Trial in ALK+ NSCLCThomas E. Stinchcombe, MD, discusses the results of the randomized phase III ALTA-1L trial in ALK-positive non–small cell lung cancer.
Latest:
Dr. Witzig on Emerging Agents in Diffuse Large B-Cell LymphomaThomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the emerging agents being utilized in the treatment of patients with diffuse large B-cell lymphoma.
Latest:
Dr. Gajewski on Targets Being Explored in MelanomaThomas F. Gajewski, MD, PhD, professor of medicine at The University of Chicago Medicine, discusses what targets are currently being explored in patients with melanoma.
Latest:
Dr. Martin on the Patient Population of the CARTITUDE-1 Study in R/R Multiple MyelomaThomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.
Latest:
Similarity of Biosimilars and BiologicsThomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.
Latest:
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of RelapseThomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.
Latest:
Dr. Herzog on the FDA Approval of Mirvetuximab Soravtansine in FRα–positive Gynecologic CancersThomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.
Latest:
Dr. Hope on the Impact of Using 68Ga-PSMA-11 to Detect Pelvic Nodal Metastasis in Prostate CancerThomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.
